Business Wire

Octapharma: New Consensus Recommendations on Treatment of Secondary Antibody Deficiency in Patients With Haematological Malignancies

Share

New expert consensus guidelines on the use of immunoglobulin replacement therapy (IgRT) in patients with haematological malignancy and secondary antibody deficiencies (SAD) were recently published in the European Journal of Haematology.

The publication, sponsored by Octapharma, marks the first pan-European consensus guidance on the use of IgRT in patients with hypogammaglobulinaemia secondary to haematological malignancies and aims to support harmonisation of clinical practice across Europe.

Octapharma has a longstanding commitment to improving the management of patients with secondary immunodeficiencies (SID) and in 2020 launched PRO-SID, a phase III clinical trial investigating primary infection prophylaxis with intravenous immunoglobulin (IVIg) in patients with chronic lymphocytic leukaemia (CLL). These efforts address the need for both robust clinical data and unified guidance on managing infection risk in patients with SID.

Absence of guidance leaves patients at risk

SAD is a common complication in patients with haematological malignancies such as CLL and multiple myeloma (MM). Up to 85% of CLL patients and up to 83% of patients with smouldering MM have low immunoglobulin levels, which leaves patients more susceptible to infections1,2. Infections are the likely cause of death in 22% of patients with MM and up to 50% of patients with CLL3,4. IgRT is effective at reducing the risk of infections in patients with haematological malignancies5.

In 2019, the EMA approved an expanded use of IVIg in patients with SID6. However, detailed European guidelines on the use of IgRT in patients with haematological malignancies and SAD were lacking. Differences in treatment approaches to reduce the infection burden remain significant across Europe, including different strategies for initiation, dosing and discontinuation of IgRT.

Stephen Jolles, lead author of the publication and Professor at the Immunodeficiency Centre for Wales in Cardiff, UK, commented: “Developing consensus guidelines for the use of IgRT in secondary antibody deficiency (SAD) aims to address a major need for treatment recommendations for patients with haematological malignancies and SAD. IgRT can reduce morbidity and mortality in a selected group of these patients and it is important that physicians have consistent guidance on defining this group and managing infection risk.”

A Task Force of eight experts in immunology and haemato-oncology developed statements on key aspects of IgRT, which were reviewed by a panel of 32 European experts. This Delphi consensus exercise developed clear recommendations for SAD due to haematological malignancies such as: measurement of IgG levels at the beginning of anti-cancer treatment; initiation of IgRT in patients who have received appropriate anti-infective therapy during or after a single severe infection or during recurrent or persistent infections when IgG levels are <4 g/l or if test immunization has failed; initiation of IgRT with a minimum IgG dose of 0.4 g/kg bodyweight every 3-4 weeks or stopping IgRT after at least 6 months without infections and concomitant evidence of immunological recovery. The 21 consensus statements emphasise the importance of IgRT for patients with SAD who experience severe, recurrent or persistent infections and provide guidance on initiation, dosing and discontinuation of IgRT, as well as measurement of IgG levels and the use of subcutaneous immunoglobulin (SCIg) therapy. The publication is available through open access at "Treating Secondary Antibody Deficiency in Patients with Haematological Malignancy: European Expert Consensus".

More information on SID in patients with haematological malignancies, including detailed information on the recent consensus guidelines, can be found at https://www.secondaryimmunodeficiency.com/

Patient recruitment continues for the PRO-SID study

Recruitment for the phase III PRO-SID study (NCT04502030) of IVIg in patients with CLL and SID is underway, in 22 sites across 7 countries. The PRO-SID study is investigating the efficacy and safety of IVIg (Panzyga®) as primary prophylaxis in patients with CLL and SID. Secondary prophylaxis with IVIg is an established approach to reduce the rate of infections in patients with haematological malignancies and SAD, but there is a need for robust data on IVIg as primary infection prophylaxis, i.e. before a major infection occurs7.

Commenting on Octapharma’s involvement in the field of SID, Olaf Walter, Board Member at Octapharma, said that: “Infections remain a serious concern for patients with haematological malignancies and SID, and at Octapharma we continue to strive for a better understanding of how to minimise the risk of such potentially life-threatening complications.”

About the PRO-SID study

The PRO-SID study (NCT04502030) is a prospective, double-blind, randomised, multi-centre, placebo-controlled, interventional, phase III study investigating the efficacy and safety of Panzyga® in patients with chronic lymphocytic leukaemia (CLL) and hypogammaglobulinaemia (IgG < 5 g/L) who are receiving antineoplastic treatment. The study is conducted at multiple sites across Europe (Italy, Poland, Denmark, Hungary, Germany and Russia) and the USA and plans to recruit at least 240 patients.

About Panzyga®

Panzyga® is a 10% human normal immunoglobulin solution ready for intravenous administration. Panzyga® is approved for use in treatment of primary immunodeficiency and idiopathic thrombocytopenic purpura in the USA, Europe and Canada. It is also approved for secondary immunodeficiencies and Guillain Barré syndrome in Europe and Canada and for Kawasaki disease, chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN) in Europe.

About Octapharma

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines.

Octapharma employs more than 9,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Haematology, Immunotherapy, and Critical Care.

Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden, and operates more than 160 plasma donation centres across Europe and the USA.

References

  1. Patel SY, Carbone J, Jolles S. The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management. Frontiers in Immunology 2019; 10 (DOI: 10.3389/fimmu.2019.00033).
  2. Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, Larson DR, Plevak MF, Jelinek DF, Fonseca R, Melton LJ, Rajkumar SV. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007; 356:2582-90.
  3. Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bjorkholm M, Hultcrantz M, Kjellander C, Turesson I, Kristinsson SY. Multiple myeloma and infections. Haematologica 2015; 100:107-13.
  4. Compagno N, Malipiero G, Cinetto F, Agostini C. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. Frontiers in Immunology 2014; 5:626.
  5. Benbrahim O, Viallard J-F, Choquet S, Royer B, Bauduer F, Decaux O, Crave J-C, Fardini Y, Clerson P, Lévy V. The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments. Hematology 2019; 24:173-82.
  6. EMA. Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) 2019; https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-smpc-human-normal-immunoglobulin-intravenous-administration-ivig-rev-5_en.pdf
  7. Agostini C, et al. Prophylactic immunoglobulin therapy in secondary immune deficiency – an expert opinion. Expert Rev Clin Immunol 2016; 12:921-926.

Contact information

Ivana Spotakova
Communications Manager
ivana.spotakova@octapharma.com
Tel.: +41793474607

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

L&T Technology Services Selected by Airbus for Skywise Partner Programme25.2.2021 08:04:00 CETPress release

L&T Technology Services (NSE: LTTS), a leading global pure-play engineering services company, announced that it has been selected by Airbus to provide technology and digital engineering solutions for Airbus’ Skywise platform as part of the ‘Skywise Partner Programme’. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224006261/en/ Abhishek Sinha, Chief Operating Officer and Board Member LTTS with Rémi Maillard, President & Managing Director, Airbus India & South Asia, commemorate LTTS joining the Skywise Partner Program (Photo: Business Wire) With more than 130 airlines around the world already connected to Skywise, the platform is playing a very important part in enabling and accelerating digital transformation of the aviation sector as a whole. LTTS will support the airlines in the development of complex workflows, creation of new interfaces between their existing information systems and Skywise and also provide assistance

Ecoppia Strengthens Its Presence in the Middle East with a first Project in Egypt25.2.2021 08:00:00 CETPress release

Ecoppia (TASE:ECPA), the pioneer and world leader in robotic solutions for photovoltaic solar, announced today a new project in one of the worlds’ largest solar parks in BenBan, Egypt. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005973/en/ Ecoppia's light-weighted T4 solution, designed especially for Single Axis trackers. Completely autonomous, water-free, and energy independent. (Photo: Business Wire) BenBan solar park, located near the southern Egyptian city of Aswan, has a total capacity of 1,650 MWp corresponding to an annual production of approximately 3.8 TW, and is spread across nearly 40 km. While enjoying very high radiation rates, the facility also suffers from major soiling and desert sands, requiring frequent cleaning to ensure steady and optimal production. Ecoppia’s robotic solutions were proven to be extremely effective, cleaning nearly 10 million solar panels every night in harsh climatic conditions,

SES S.A.: Full Year 2020 Results25.2.2021 07:30:00 CETPress release

SES S.A. announces financial results for the year ended 31 December 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224006241/en/ SES S.A.: Full Year 2020 Results Third successive year delivering EBITDA outlook despite challenging COVID-19 environment in 2020 Growth engine Networks revenue +5% YOY(1,2), or +27% since 2017, and Video revenue of €1,108 million in line with expectations Adjusted EBITDA(3) of €1,152 million delivered within pre-COVID-19 financial outlook and at high end of mid-year outlook Strong net cash generated from operations of €1,049 million representing 97% of reported EBITDA Commitment to disciplined financial policy and shareholder returns Solid cash flow generation driving €505 million YOY debt reduction and lowest leverage ratio(4) (of 2.97 times) over the past 5 years Proposed 2020 dividend of €0.40 per A-share consistent with commitment to maintain a minimum base dividend of €0.40 On track

SES Extends Long-Term Partnership With Sky25.2.2021 07:00:00 CETPress release

Sky UK has extended its contract with SES for satellite capacity in a new agreement that will add over EUR 90 million in secured backlog. This renewal is in addition to capacity already under contract that extends through 2027. By the end of the renewed contract, Sky UK will have been an SES customer continuously for almost four decades, illustrating the strength and value of the partnership to Sky UK’s business in terms of the reliability, performance, high-quality viewing experience and the reach of SES’s satellite services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224006139/en/ SES Extends Long-Term Partnership With Sky (Photo: Business Wire) As part of the contract, SES will deliver Sky UK’s channels in a mix of standard definition (SD), high definition (HD) and ultra-high definition (UHD) from the 28.2/28.5 degrees East orbital slots to the operator’s subscribers across the United Kingdom and Republic of Irelan

ADVA announces record Q4 2020 results and reports full year 2020 figures25.2.2021 07:00:00 CETPress release

ADVA (ISIN: DE0005103006), a leading provider of open networking solutions for the delivery of cloud and mobile services, reported financial results for Q4 2020 and full year 2020 ended on December 31, 2020. The results have been prepared in accordance with International Financial Reporting Standards (IFRS). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005994/en/ Brian Protiva, CEO, ADVA (Photo: Business Wire) Q4 2020 financial summary1 (in thousands of EUR) Q4 Q4 Change Q3 Change 2020 2019 2020 Revenues 140,572 151,135 -7.0% 146,676 -4.2% Pro forma gross profit 54,641 54,633 0.0% 51,930 5.2% in % of revenues 38.9% 36.1% 2.8pp 35.4% 3.5pp Pro forma operating income 14,343 10,333 38.8% 11,053 29.8% in % of revenues 10.2% 6.8% 3.4pp 7.5% 2.7pp Operating income (loss) 13,085 5,438 140.6% 9,768 34.0% Net income 13,249 2,522 425.3% 6,671 98.6% (in thousands of EUR) Dec. 31 Dec. 31 Change Sep. 30 Change 2020 2019 2020 Cash

Protembis Announces Completion of 20 Cases in European CE Mark Study With the ProtEmbo ® Cerebral Protection System25.2.2021 06:15:00 CETPress release

Protembis GmbH, a privately held emerging medical device company, announced today the successful completion of 20 clinical cases in its European regulatory study of the ProtEmbo® Cerebral Protection System. The ProtEmbo® System is an intra-aortic filter device that deflects embolic material away from the brain during transcatheter aortic valve replacement (TAVR). The device is a low profile system which is delivered through the left radial artery, an ideal access site enabling physicians to avoid interference with TAVR equipment, typically delivered through the left femoral artery. Nikos Werner, M.D., Professor of Medicine, Head of Cardiology at the Heart Center Trier, Germany, and Principal Investigator in Germany commented: “Embolic protection in TAVR procedures has been shown to be effective in reducing the ischemic burden in the brain, but physicians look forward to next generation devices that are easy to use, cover all three potential access arteries to the brain, and can be simp

Wipro Marks 25 Years of Partnership With Cisco; Launches Cisco Business Unit25.2.2021 06:00:00 CETPress release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting, and business process services company, is celebrating the 25th anniversary of its business partnership with Cisco (NASDAQ: CSCO), the worldwide leader in technology that powers the Internet. To commemorate this milestone, Wipro is launching the Cisco Business Unit that will focus on the development and adoption of end-to-end digital transformation solutions leveraging Cisco technologies for customers. This strategic initiative demonstrates Wipro’s commitment to its business relationship with Cisco. Also, it is a growth accelerator for the successful and well-established 360-degree partnership of several years. Over the course of 25 years, Wipro has focused on delivering its transformative service capabilities across Digital, Cloud, Security, and Engineering, which are aligned with Cisco’s operational priorities. Wipro and Cisco co-develop communications, infrastructure, and security

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom